Infudopa SubC™ is a levodopa-carbidopa solution that is administered subcutaneously using a portable belt pump and intended as monotherapy for outpatient treatment of Parkinson´s disease with moderate to severe on-off symptoms. Infudopa SubC™ has a pH optimizing levodopa uptake from the subcutaneous tissue and minimizing the risk of side effects at the injection site.
The shelf life for this product is 30 months in refrigerator and a minimum of 3 months at room temperature. This excellent stability represents a considerable logistical advantage for patients, e.g. when travelling.
Dizlin Pharmaceuticals plans to file the application for marketing authorization of Infudopa SubC™ in Europe and in the US in late 2022 or early 2023.
Infudopa IntraV™ is a levodopa-carbidopa solution intended for treatment of inpatients for which enteral levodopa administration is infeasible, e.g. before or after surgery, as well as for inpatients where marked on-off symptomatology prevents various diagnostics procedures or surgery.
Dizlin Pharmaceuticals plans to file the application for marketing authorization of Infudopa IntraV™ in Europe and in the US during 2022.